134 related articles for article (PubMed ID: 20923040)
1. Metabolic syndrome after hormone-modifying therapy: risks associated with antineoplastic therapy.
Redig AJ; Munshi HG
Oncology (Williston Park); 2010 Aug; 24(9):839-44. PubMed ID: 20923040
[TBL] [Abstract][Full Text] [Related]
2. Care of the cancer survivor: metabolic syndrome after hormone-modifying therapy.
Redig AJ; Munshi HG
Am J Med; 2010 Jan; 123(1):87.e1-6. PubMed ID: 20102997
[TBL] [Abstract][Full Text] [Related]
3. Metabolic complications of androgen deprivation therapy for prostate cancer.
Saylor PJ; Smith MR
J Urol; 2013 Jan; 189(1 Suppl):S34-42; discussion S43-4. PubMed ID: 23234628
[TBL] [Abstract][Full Text] [Related]
4. Metabolic and cardiovascular effects of androgen deprivation therapy.
Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
[TBL] [Abstract][Full Text] [Related]
5. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
[TBL] [Abstract][Full Text] [Related]
6. Risk of metabolic syndrome, cardiovascular disease, and diabetes in androgen deprivation therapy.
Leahy Y
Clin J Oncol Nurs; 2008 Oct; 12(5):771-6. PubMed ID: 18842533
[TBL] [Abstract][Full Text] [Related]
7. [Metabolic impact of androgen deprivation therapy for prostate cancer].
Andrès E; Eschwege P; Lang H; Moreau JL; Peiffert D; Thiery-Vuillemin A; Kleinclauss F
Prog Urol; 2012 Sep; 22 Suppl 2():S39-47. PubMed ID: 23098789
[TBL] [Abstract][Full Text] [Related]
8. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
Harrington JM; Schwenke DC; Epstein DR; Bailey DE
Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236
[TBL] [Abstract][Full Text] [Related]
9. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
Basaria S
J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
[TBL] [Abstract][Full Text] [Related]
10. Considering metabolic effects when making breast cancer treatment decisions.
Ligibel JA
Oncology (Williston Park); 2010 Aug; 24(9):844-6. PubMed ID: 20923041
[No Abstract] [Full Text] [Related]
11. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
[TBL] [Abstract][Full Text] [Related]
12. Emerging cardiometabolic complications of androgen deprivation therapy.
Choong K; Basaria S
Aging Male; 2010 Mar; 13(1):1-9. PubMed ID: 20148744
[TBL] [Abstract][Full Text] [Related]
13. Metabolic effects of hormone deprivation therapy: weighing the evidence.
Van Londen GJ; Lembersky BC
Oncology (Williston Park); 2010 Aug; 24(9):846-7. PubMed ID: 20923042
[No Abstract] [Full Text] [Related]
14. Managing hot flashes in men being treated for prostate cancer.
Baum NH; Torti DC
Geriatrics; 2007 Nov; 62(11):18-21. PubMed ID: 17999566
[TBL] [Abstract][Full Text] [Related]
15. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review.
Collier A; Ghosh S; McGlynn B; Hollins G
Am J Clin Oncol; 2012 Oct; 35(5):504-9. PubMed ID: 21297430
[TBL] [Abstract][Full Text] [Related]
17. Metabolic syndrome and prostate cancer: a review.
Nobes JP; Langley SE; Laing RW
Clin Oncol (R Coll Radiol); 2009 Apr; 21(3):183-91. PubMed ID: 19111451
[TBL] [Abstract][Full Text] [Related]
18. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.
Conteduca V; Di Lorenzo G; Tartarone A; Aieta M
Crit Rev Oncol Hematol; 2013 Apr; 86(1):42-51. PubMed ID: 23092636
[TBL] [Abstract][Full Text] [Related]
19. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
Braga-Basaria M; Dobs AS; Muller DC; Carducci MA; John M; Egan J; Basaria S
J Clin Oncol; 2006 Aug; 24(24):3979-83. PubMed ID: 16921050
[TBL] [Abstract][Full Text] [Related]
20. Estrogen-replacement therapy in younger women with breast cancer.
Theriault RL; Sellin RV
J Natl Cancer Inst Monogr; 1994; (16):149-52. PubMed ID: 7999457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
